Rationality of performing hyperthermic intraperitoneal chemotherapy 5-8 weeks after primary tumor resection for patients with locally advanced colorectal cancer—based on COLOPEC
10.3760/cma.j.issn.1671-0274.2019.12.004
- VernacularTitle: 局部进展期结直肠癌原发肿瘤切除术后5~8周行腹腔热灌注化疗的合理性
- Author:
Ziying LEI
1
;
Tianpei GUAN
1
;
Jiali LUO
2
;
Hongsheng TANG
1
;
Shuzhong CUI
1
Author Information
1. Department of Abdominal Surgery, Affiliated Cancer Hospital & Institute, Guangzhou Medical University, Guangzhou 510095, China
2. Department of Oncology, Guangzhou Medical University, Guangzhou 510095, China
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms, advanced;
Hyperthermic intraperitoneal chemotherapy;
Peritoneal metastases;
Clinical trial
- From:
Chinese Journal of Gastrointestinal Surgery
2019;22(12):1115-1117
- CountryChina
- Language:Chinese
-
Abstract:
Hyperthermic intraperitoneal chemotherapy (HIPEC) has a unique effect on the prevention and treatment of peritoneal metastasis from malignancies. Recently, the first prospective, multicenter, randomized controlled clinical trial of HIPEC to prevent the development of peritoneal metastasis after curative surgery for patients with locally advanced colon cancer was published in the "Lancet Gastroenterol Hepatol" (COLOPEC). Regrettably, no significant difference was observed in 18-month peritoneal metastasis-free survival between postoperative adjuvant HIPEC and standard systemic chemotherapy for patients with T4 stage or perforated colon cancer. However, we wonder whether we might achieve better outcomes by further optimizing the following issues: (1) We propose that the inclusion criteria for that trial may not be entirely reasonable, which included pT4N0-2M0 and perforation. Additionally, we found that 91% of patients underwent HIPEC 5-8 weeks after primary tumor resection. (2) The imbalance in starting time of postoperative systemic chemotherapy between the two groups may have a negative impact.(3) Nine patients with peritoneal metastasis preceding HIPEC might weaken the potential efficacy of HIPEC. (4) We wonder whether HIPEC using high-dese oxaliplatin (460 mg/m2) perfusing 30 minutes for one cycle is the optimal regimen. Therefore, we are planning to conduct a randomized controlled trial (HIPEC-06) in accordcance with the characteristics of Chinese patients, to explore the clinical efficacy of curative surgery combined with HIPEC in the treatment of cT4 colorectal cancer.
